However, in our selected validation cohort (GSE28735), which contains 45 pancreatic cancer patients with overall survival time, we observed that SLC16A1 and SLC16A3 only demonstrate the same trend if separated the patients into high and low groups at median expression. Here, SLC16A1 is linked to familial pancreatic carcinoma.